A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity

Carmela Gallo, Giusi Barra, Marisa Saponaro, Emiliano Manzo, Laura Fioretto, Marcello Ziaco, Genoveffa Nuzzo, Giuliana d'Ippolito, Raffaele De Palma, Angelo Fontana

Research output: Contribution to journalArticlepeer-review

Abstract

Immunotherapy takes advantage of the immune system to prevent, control, and eliminate neoplastic cells. The research in the field has already led to major breakthroughs to treat cancer. In this work, we describe a platform that integrates in vitro bioassays to test the immune response and direct antitumor effects for the preclinical discovery of anticancer candidates. The platform relies on the use of dendritic cells that are professional antigen-presenting cells (APC) able to activate T cells and trigger a primary adaptive immune response. The experimental procedure is based on two phenotypic assays for the selection of chemical leads by both a panel of nine tumor cell lines and growth factor-dependent immature mouse dendritic cells (D1). The positive hits are then validated by a secondary test on human monocyte-derived dendritic cells (MoDCs). The aim of this approach is the selection of potential immunotherapeutic small molecules from natural extracts or chemical libraries.

Original languageEnglish
JournalMarine Drugs
Volume18
Issue number12
DOIs
Publication statusPublished - Nov 29 2020

Keywords

  • anticancer
  • bioassay platform
  • chemical immunology
  • dendritic cell
  • drug discovery
  • high throughput
  • immunotherapy
  • screening guidelines

ASJC Scopus subject areas

  • Drug Discovery

Fingerprint Dive into the research topics of 'A New Bioassay Platform Design for the Discovery of Small Molecules with Anticancer Immunotherapeutic Activity'. Together they form a unique fingerprint.

Cite this